Journal article
Quality‐of‐life outcomes in patients with advanced melanoma: A review of the literature
Pigment cell and melanoma research, Vol.30(6), pp.511-520
11/2017
DOI: 10.1111/pcmr.12647
PMID: 28950054
Abstract
Summary
For patients with metastatic melanoma, the emergence of immune checkpoint inhibitors and targeted BRAF and MEK inhibitors has markedly enhanced clinical outcomes compared with chemotherapy. However, these novel agents are also associated with unique sets of adverse events, and increased overall survival can lead to prolonged exposure to some novel agents. Therefore, clinical evaluation of these therapies has now included the analysis of health‐related quality of life (HRQoL) in addition to more traditional efficacy and safety outcomes as a measure of patient perception of benefit. The current review focuses on HRQoL outcomes in clinical trials of immune checkpoint inhibitors and targeted therapies in patients with advanced and metastatic melanoma to inform healthcare providers about patient perception of HRQoL as a new perspective in treatment decision making.
Details
- Title: Subtitle
- Quality‐of‐life outcomes in patients with advanced melanoma: A review of the literature
- Creators
- Karen A. Malkhasyan - University of IowaYousef Zakharia - University of IowaMohammed Milhem - University of Iowa Hospitals and Clinics
- Resource Type
- Journal article
- Publication Details
- Pigment cell and melanoma research, Vol.30(6), pp.511-520
- DOI
- 10.1111/pcmr.12647
- PMID
- 28950054
- NLM abbreviation
- Pigment Cell Melanoma Res
- ISSN
- 1755-1471
- eISSN
- 1755-148X
- Number of pages
- 10
- Grant note
- Novartis Pharmaceuticals Corporation
- Language
- English
- Date published
- 11/2017
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984360060202771
Metrics
14 Record Views